BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Astrocytoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
1935 results:

  • 1. egfr/CEP7 high polysomy is separate and distinct from egfr amplification in glioblastoma as determined by fluorescence in situ hybridization.
    Wilcock DM; Goold E; Zuromski LM; Davidson C; Mao Q; Sirohi D
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):338-344. PubMed ID: 38605523
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases.
    Kibe Y; Ohka F; Aoki K; Yamaguchi J; Motomura K; Ito E; Takeuchi K; Nagata Y; Ito S; Mizutani N; Shiba Y; Maeda S; Nishikawa T; Shimizu H; Saito R
    Acta Neuropathol Commun; 2024 Apr; 12(1):57. PubMed ID: 38605367
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Exploring ncRNA-mediated regulation of egfr signalling in glioblastoma: From mechanisms to therapeutics.
    Thapa R; Afzal M; Goyal A; Gupta G; Bhat AA; Almalki WH; Kazmi I; Alzarea SI; Shahwan M; Kukreti N; Ali H; Dureja H; Kumar P; Singh TG; Kuppusamy G; Singh SK; Dua K
    Life Sci; 2024 May; 345():122613. PubMed ID: 38582393
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Mesenchymal glioma stem cells trigger vasectasia-distinct neovascularization process stimulated by extracellular vesicles carrying egfr.
    Spinelli C; Adnani L; Meehan B; Montermini L; Huang S; Kim M; Nishimura T; Croul SE; Nakano I; Riazalhosseini Y; Rak J
    Nat Commun; 2024 Apr; 15(1):2865. PubMed ID: 38570528
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Quantifying intra-tumoral genetic heterogeneity of glioblastoma toward precision medicine using MRI and a data-inclusive machine learning algorithm.
    Wang L; Wang H; D'Angelo F; Curtin L; Sereduk CP; Leon G; Singleton KW; Urcuyo J; Hawkins-Daarud A; Jackson PR; Krishna C; Zimmerman RS; Patra DP; Bendok BR; Smith KA; Nakaji P; Donev K; Baxter LC; Mrugała MM; Ceccarelli M; Iavarone A; Swanson KR; Tran NL; Hu LS; Li J
    PLoS One; 2024; 19(4):e0299267. PubMed ID: 38568950
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Targeting the egfr pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
    Schachenhofer J; Gruber VE; Fehrer SV; Haider C; Glatter S; Liszewska E; Höftberger R; Aronica E; Rössler K; Jaworski J; Scholl T; Feucht M
    Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12974. PubMed ID: 38562027
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Molecular and functional insight into anti-egfr nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Comprehensive mutational scanning of egfr reveals TKI sensitivities of extracellular domain mutants.
    Hayes TK; Aquilanti E; Persky NS; Yang X; Kim EE; Brenan L; Goodale AB; Alan D; Sharpe T; Shue RE; Westlake L; Golomb L; Silverman BR; Morris MD; Fisher TR; Beyene E; Li YY; Cherniack AD; Piccioni F; Hicks JK; Chi AS; Cahill DP; Dietrich J; Batchelor TT; Root DE; Johannessen CM; Meyerson M
    Nat Commun; 2024 Mar; 15(1):2742. PubMed ID: 38548752
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Integrative multi-omics characterization reveals sex differences in glioblastoma.
    Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
    Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
    Choi BD; Gerstner ER; Frigault MJ; Leick MB; Mount CW; Balaj L; Nikiforow S; Carter BS; Curry WT; Gallagher K; Maus MV
    N Engl J Med; 2024 Apr; 390(14):1290-1298. PubMed ID: 38477966
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Crosstalk between purinergic receptor P2Y
    Klaver D; Gander H; Frena B; Amato M; Thurnher M
    Cell Mol Life Sci; 2024 Mar; 81(1):132. PubMed ID: 38472446
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. AGCM-22, a novel cetuximab-based egfr-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
    Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
    Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
    Ezzati S; Salib S; Balasubramaniam M; Aboud O
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396993
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.
    Repici A; Ardizzone A; De Luca F; Colarossi L; Prestifilippo A; Pizzino G; Paterniti I; Esposito E; Capra AP
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391974
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Exploring the therapeutic mechanisms and prognostic targets of Biochanin A in glioblastoma via integrated computational analysis and in vitro experiments.
    Ge W; Yuan G; Wang D; Dong L
    Sci Rep; 2024 Feb; 14(1):3783. PubMed ID: 38360888
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [PET/CT with 11C-methionine in assessment of brain glioma metabolism].
    Vikhrova NB; Kalaeva DB; Tyurina AN; Belyaev AY; Danilov GV; Pronin IN
    Zh Vopr Neirokhir Im N N Burdenko; 2024; 88(1):63-69. PubMed ID: 38334732
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to egfr and erbb2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.
    Kiefer A; Prüfer M; Röder J; Pfeifer Serrahima J; Bodden M; Kühnel I; Oberoi P; Wels WS
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334638
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
    Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
    J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Molecular signature of stem-like glioma cells (SLGCs) from human glioblastoma and gliosarcoma.
    Zechel C; Loy M; Wegner C; Dahlke E; Soetje B; Baehr L; Leppert J; Ostermaier JJ; Lueg T; Nielsen J; Elßner J; Willeke V; Marzahl S; Tronnier V; Madany Mamlouk A
    PLoS One; 2024; 19(2):e0291368. PubMed ID: 38306361
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (egfr BATs) in combination with radiation and temozolomide.
    Fadul CE; Thakur A; Kim J; Kassay-McAllister J; Schalk D; Lopes MB; Donahue J; Purow B; Dillon P; Le T; Schiff D; Liu Q; Lum LG
    J Neurooncol; 2024 Jan; 166(2):321-330. PubMed ID: 38263486
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 97.